This company listing is no longer active
Toleranzia (TOL) Stock Overview
A biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
TOL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Toleranzia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.48 |
| 52 Week High | SEK 0.72 |
| 52 Week Low | SEK 0.27 |
| Beta | 0.98 |
| 1 Month Change | 5.30% |
| 3 Month Change | 3.25% |
| 1 Year Change | -3.44% |
| 3 Year Change | -54.13% |
| 5 Year Change | -74.22% |
| Change since IPO | -94.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| TOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.6% | -0.5% | 0.4% |
| 1Y | -3.4% | 19.5% | 10.5% |
Return vs Industry: TOL exceeded the Swedish Biotechs industry which returned -10.2% over the past year.
Return vs Market: TOL underperformed the Swedish Market which returned 0.9% over the past year.
Price Volatility
| TOL volatility | |
|---|---|
| TOL Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: TOL has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: TOL's weekly volatility has decreased from 10% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Charlotte Fribert | www.toleranzia.se |
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease.
Toleranzia AB (publ) Fundamentals Summary
| TOL fundamental statistics | |
|---|---|
| Market cap | SEK 129.25m |
| Earnings (TTM) | -SEK 13.24m |
| Revenue (TTM) | SEK 28.21m |
Is TOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOL income statement (TTM) | |
|---|---|
| Revenue | SEK 28.21m |
| Cost of Revenue | SEK 32.45m |
| Gross Profit | -SEK 4.23m |
| Other Expenses | SEK 9.01m |
| Earnings | -SEK 13.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 11, 2025
| Earnings per share (EPS) | -0.049 |
| Gross Margin | -15.00% |
| Net Profit Margin | -46.92% |
| Debt/Equity Ratio | 2.9% |
How did TOL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/21 15:58 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Toleranzia AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.